Yiyun Tang - Concepedia

Author

Yiyun Tang

Also Known As

Esserman, Denise, Tang, Yiyun, Xiao-Qing Tang, Y Tang, Y. H. Tang, Y. Tang, Yi-Yun Tang, Yinqing Tang, Yiyun Tang, Yi‐Yun Tang

107

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of South China Massachusetts General Hospital First Affiliated Hospital of University of South China Dana-Farber Cancer Institute

About

Yiyun Tang is an author at Pfizer (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	2.7K
2	Social Sciences	6	6	200
3	Health Sciences	5	5	152
4	Biochemistry	5	5	157
5	Natural Sciences	1	1	30

Yiyun Tang

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, The Lancet Oncology OncologyMedicineUpdated ResultsPathologyBronchial Neoplasm	2012	1.3K
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, The Lancet Oncology Overall SurvivalAlk Gene RearrangementMedicineRetrospective AnalysisPathology	2011	880
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer Benjamin Solomon, Dong‐Wan Kim, Yi‐Long Wu, Journal of Clinical Oncology	2018	406
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer Stephen J. Freedland, Murilo Luz, Ugo De Giorgi, New England Journal of Medicine	2023	245
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC S.-H.I. Ou, Pasi A. Jänne, Cynthia Huang Bartlett, Annals of Oncology	2014	220
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer Yi‐Long Wu, Shun Lü, You Lü, Journal of Thoracic Oncology	2018	181
Crizotinib in Patients With MET-Amplified NSCLC D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Journal of Thoracic Oncology	2021	163
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations Tony Mok, Ying Cheng, Xiangdong Zhou, Drugs	2020	115
Adjusting overall survival for treatment switches: commonly used methods and practical application Claire Watkins, Xin Huang, Nicholas Latimer, Pharmaceutical Statistics	2013	86
Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Journal of Clinical Oncology Preclinical TherapeuticsCardiovascular PharmacologyPathologyPharmacotherapyPre-clinical Pharmacology	2018	79

Page 1